5,5'-[(2R,5R)-1-[3,5-Difluoro-4-[4-(4-Fluorophenyl)-1-Piperidinyl]Phenyl]-2,5-Pyrrolidinediyl]Bis[6-Fluoro-2-(2S)-2-Pyrrolidinyl-1H-Benzimidazole]

In the convergent assembly of second‑generation hepatitis C NS5A phosphoprotein inhibitors, the symmetrical bis‑benzimidazole framework acts as the critical dimerization core that confers picomolar potency against genotype 1a replicons. The compound enters the manufacturing stream as a regioisomerically pure free base, dissolved in anhydrous N,N‑dimethylacetamide containing 3% lithium chloride to suppress aggregation, and is subjected to a copper‑free Sonogashira‑type coupling with a functionalized ethynyl‑piperidine fragment. Stoichiometric discipline is maintained with a molar excess of 1.10–1.15 equivalents relative to the alkyne partner, ensuring that the less reactive chlorine substituent on the central phenyl ring remains unperturbed below 80 °C. Compliance with ICH Q7 8.30 and FDA 21 CFR 211.110 necessitates in‑process HPLC monitoring every 30 minutes until the intermediate peak area drops below 0.5%; batches failing this criterion are diverted to preparative chromatography. The post‑reaction workup entails a solvent exchange into isopropyl acetate and a pH‑adjusted aqueous wash to remove lithium salts and residual DMAc, followed by polish filtration through a 0.45 µm polypropylene membrane. The purified wet cake is dried under vacuum (≤−0.095 MPa) at 55 °C for 24 h, yielding a crystalline solid with an assay of ≥99.0%. Its integration into the final dosage form follows a direct compression route: the dried free base is blended with Prosolv® SMCC 90 and Ac‑Di‑Sol® at a drug load of 25.0 wt% and compressed into film‑coated tablets having a tensile strength of ≥1.7 MPa and a disintegration time under 5 minutes in 900 mL of pH 6.8 phosphate buffer.

At What Molar Ratio Does the Bis‑Benzimidazole Core Suppress Epimerization in Amide Bond Formation?

The generation of the final amide linkage between the pyrrolidine amine of this intermediate and the valine‑derived acid fragment presents a documented risk of epimerization at the pyrrolidine 2‑position, a chiral center whose stereochemical integrity directly governs antiviral potency in infected hepatocyte models. When the nucleophilic amine is employed at a ratio of 1.05 equivalents to 1.00 equivalent of the pre‑activated pentafluorophenyl ester dissolved in 2‑methyltetrahydrofuran, the coupling conducted at −5 to 0 °C consistently yields the desired diastereomer with <0.3% of the (2R)‑epimer as quantified by chiral HPLC (Chiralpak IA, 250×4.6 mm, 5 µm). Any departure beyond 1.10 equivalents increases the concentration of unreacted free amine, which catalyzes proton transfer at the α‑carbon and elevates the epimer level to 1.8–2.2%, exceeding the qualification threshold of ICH Q3A. The manufacturing protocol therefore locks the stoichiometric ratio through mass flow controllers regulating the pentafluorophenyl ester addition pump, a unit operation validated under cGMP per 21 CFR 211.68. The reaction mass is quenched into a biphasic mixture of n‑heptane and ethyl acetate (85:15 v/v), from which the amide intermediate precipitates; it is isolated on a Hastelloy C‑22 filter dryer, washed with cold water to remove pentafluorophenol, and dried at 45 °C under a nitrogen sweep until loss on drying falls below 0.5%. The resulting amorphous solid is directly transformed into the methanesulfonate salt in acetone, spray‑dried to a controlled particle size distribution (D90 < 20 µm), and encapsulated into hydroxypropyl methylcellulose capsules for once‑daily oral administration as a finished antiviral drug product.

Pharmacopeial Reference Standard Certification and Forced Degradation Product Inventory

A dedicated portion of the production batch is diverted into a high‑purity refining sequence to generate an official reference standard compliant with ISO 17034 and the general chapter USP <11>. The crude material is dissolved in a mixture of acetonitrile and deionized water containing 0.1% trifluoroacetic acid and subjected to a two‑stage preparative HPLC protocol using a C18 column (250×50 mm, 10 µm) with isocratic elution at 254 nm. Fractions collected from the heart of the main peak are pooled, rotary‑evaporated at 35 °C, and lyophilized for 72 h to afford a powder with a chromatographic purity of ≥99.92% against area normalization. The certified standard is dissolved in methanol to a concentration of 0.1000 mg/mL and dispensed into 2 mL amber glass vials sealed under argon, each labeled with a target uncertainty of ±0.5%. The same preparative infrastructure isolates forced degradation impurities generated by exposing the intermediate to 0.5 M methanolic sodium hydroxide at 60 °C for 8 h, producing the des‑fluoro and ring‑opened benzimidazole by‑products that are subsequently characterized by high‑resolution mass spectrometry. The terminal products are pharmaceutical secondary reference standards and impurity markers used for system suitability testing in quality control laboratories, directly supporting ongoing ICH Q7 stability programmes.

Printed circuit board laminates operating at 5G NR frequencies in the 3.3–4.2 GHz band impose simultaneous demands for low polarity, high crosslink density, and minimal moisture uptake on the curing agent. Evaluations of this fluorine‑rich diamine in a standard brominated bisphenol‑A novolac epoxy varnish (EEW 210–230 g/eq) demonstrate that a loading window of 4.2–5.8 phr shifts the main exotherm to 168–174 °C and yields a fully cured network with a glass transition temperature of 187 °C by DMA (1 Hz, 3 K/min). The cured laminate, manufactured by impregnating 7628‑style E‑glass fabric to a resin content of 52 ± 2% and pressing under 2.5 MPa at 190 °C for 120 min, achieves a dielectric constant of 3.48 and a dissipation factor of 0.0087 at 10 GHz, measured per IEC 61189‑2‑721 and meeting the IPC‑4101C /99 specification for low‑Dk materials. The finished component is a multilayer base‑station antenna board carrying UL 94 V‑0 certification; the cured matrix resists delamination for over 60 min at TMA 260 °C and maintains peel strength above 1.4 N/mm after 288 °C solder float for 30 s.

When the Fluorinated Piperidine Substituent is Required for Low Outgassing in Vacuum Encapsulants

Spacecraft power electronic modules encapsulated in potting compounds must satisfy ASTM E595 total mass loss (TML) below 1.0% and collected volatile condensable material (CVCM) below 0.1% to prevent deposition on optical surfaces. Incorporating this bis‑benzimidazole compound at 6.0–9.0 phr into a hydrogenated bisphenol‑A epoxy base (EEW 215–230 g/eq) with a cycloaliphatic diepoxide reactive diluent creates a formulated resin that undergoes a staged cure: 120 °C for 4 h followed by 160 °C for 6 h under continuous rotation at 50 rpm in a planetary vacuum mixer to eliminate entrapped air. The resulting thermoset exhibits an outgassing TML of 0.62% and CVCM of 0.06%, tested per ASTM E595 at 125 °C and 5×10⁻⁵ Torr for 24 h. The processing sequence entails pre‑heating the potting module base to 80 °C, injection under −0.095 MPa vacuum, and a ramp rate not exceeding 2 K/min to avoid gel‑time scatter. The terminal assembly is a satellite DC‑DC converter potted housing that satisfies NASA JSC outgassing requirements for low‑earth‑orbit missions while withstanding thermal cycling between −55 °C and 125 °C for 1 000 cycles without crack formation.

Residual DMAc Management During Final Solvent Displacement to Meet ICH Q3C Option 2 Limits

When N,N‑dimethylacetamide is employed as the reaction solvent during the late‑stage coupling of this intermediate, crude wet cakes routinely retain residual DMAc levels in the range of 3 000–5 000 ppm, far above the ICH Q3C Option 2 limit of 410 ppm for a Class 2 solvent in the final active pharmaceutical ingredient. The over‑limit level is addressed not by terminal drying but by a solvent displacement distillation: the separated organic phase is charged with absolute ethanol at a ratio of 1:5 v/v relative to the intermediate mass and distilled under a vacuum of −0.080 MPa until the distillate water content drops below 0.1%, a point at which DMAc carryover is suppressed to <200 ppm in the residue. The concentrated ethanolic solution is then added slowly to deionized water (10 volumes) at 25 °C, inducing immediate crystallization, and the resulting slurry is aged for 4 h before filtration. The dried solid exhibits residual DMAc below 250 ppm when analysed by headspace GC–MS per USP <467> Method IV. This sequence is executed within a closed stainless‑steel reactor train with automated solvent recovery and is validated under FDA 21 CFR 211.65 to deliver the final API that unambiguously conforms to the PhEur 5.4 residual solvent monograph.